Find upcoming presentations, industry seminars, conference appearances, CPE events, and symposiums near you!
The ruling on 340B reimbursement rate in the 2022 OPPS Rule may impact providers participating in APMs.
The 2022 Consolidated Appropriations Act will protect some hospitals from losing 340B Drug Pricing Program eligibility due to COVID-19. Read on for details.
Federal grantee 340B-covered entities should be proactive while awaiting court decisions regarding 340B pricing. Read on to learn more.
The window for 340B Drug Pricing Program recertification for hospital entities begins on August 11, 2021. Read on for recertification requirements and tips to prepare.
The U.S. House of Representatives recently passed an amendment to the appropriations bill with language aimed to protect the 340B Drug Pricing Program. Read on for more details.
Position yourself for success as you move forward in 2022. Learn how our trusted advisors can assist you with your goals in our Moving Forward video series.
HHS recently issued an advisory opinion stating that manufacturers must consider contract pharmacies an extension of 340B covered entities.
Certain manufacturers have notified 340B Program hospitals that 340B discounts may not be provided in the future for contract pharmacies.
The U.S. Court of Appeals has overturned a District Court decision by stating the HHS is within its authority to act on adjusting reimbursement formulas for hospitals participating in the 340B Program. Read on for details on the court’s decision.
The 340B Drug Pricing Program recertification period for hospital entities begins August 17, 2020. Read on for an overview of HRSA’s updated registration and recertification requirements.